Last $68.06 USD
Change Today +0.28 / 0.41%
Volume 7.6M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 8:04 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$67.64
Previous Close
$67.78
Day High
$68.21
Day Low
$67.15
52 Week High
11/25/14 - $68.21
52 Week Low
04/11/14 - $45.50
Market Cap
108.5B
Average Volume 10 Days
6.3M
EPS TTM
$3.03
Shares Outstanding
1.6B
EX-Date
01/13/15
P/E TM
22.4x
Dividend
$1.96
Dividend Yield
2.44%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 11/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Inc. Expands Presence in Asia with Singapore Acquisition

AbbVie Inc. has announced that it has acquired a manufacturing facility in Tuas Biomedical Park, Singapore that increases the firm's investment in Asia, and expands its presence in that region. The 120,000 square meter facility is specialised in the manufacturing of small molecule active pharmaceutical ingredients, and represents the first manufacturing site for AbbVie in Asia. It is anticipated to become fully operational in 2016. Furthermore, AbbVie will be adding a biologics manufacturing facility on the same property that is anticipated to become operational in 2019. The new site will add 250 new employees to AbbVie's staff including specialised positions in manufacturing, technical operations, administration, quality, information technology and supply chain.

AbbVie Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM

AbbVie Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: William J. Chase, Chief Financial Officer and Executive Vice President.

Abbvie Inc. Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme

AbbVie Inc. announced that it has released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th annual scientific meeting and education day of the Society for Neuro-Oncology, November 13, 2014 to November 16, 2014 in Miami. An objective response in oncology is a measurable response to cancer treatment. A complete response is sometimes called complete remission, and refers to the disappearance of all signs of cancer in response to cancer treatment. Of the two patients who achieved a complete response, one was enrolled in the monotherapy arm and the other in the arm evaluating ABT-414 as an addition to chemotherapy. These patients each had disease that recurred after radiation and chemotherapy a patient population where effective therapies are very limited.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $68.06 USD +0.28

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.24 USD -1.94
AstraZeneca PLC 4,676 GBp -35.00
Bristol-Myers Squibb Co $58.52 USD -0.35
Eli Lilly & Co $66.85 USD -0.08
Novo Nordisk A/S kr266.50 DKK 0.00
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 29.6x
Price/Sales 5.5x
Price/Book 23.2x
Price/Cash Flow 29.1x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.